Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-302 plus Abiraterone in mCRPC
NCT07104617Phase 2Not yet recruiting
- Sponsor
- TYK Medicines
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ty-302 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by TYK Medicines. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ty-302
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07104617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104617.